Differential Immune Effects of Natalizumab

Cantonal Hospital of St. Gallen

Status: Completed

Conditions: Multiple Sclerosis, Relapsing Remitting

Study type: Observational

Funder types: Other

Identifiers

NCT00859482

Ntz-Tregs1

Details and patient eligibility

About

Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.

Full description

Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).

Enrollment: 27 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• relapsing remitting MS
• indication for natalizumab treatment

Exclusion criteria

• other disease modifying agents within 2 weeks